Brooke Chapman

Ms. Brooke Chapman

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2020 in World Journal of Hepatology
Verified
Journal Article
Open access
BCBrooke Chapman
Brooke Chapman
MSMarie Sinclair
Marie Sinclair
PGPaul J Gow
Paul J Gow
ATAdam G Testro
Adam G Testro
Malnutrition in cirrhosis: More food for thought

1 October 2021 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
LPLoris Pironi
Loris Pironi
ESEzra Steiger
Ezra Steiger
FJFrancisca Joly
Francisca Joly
PJPalle B. Jeppesen
Palle B. Jeppesen
GWGeert Wanten
Geert Wanten
DJDenise Jezerski
Denise Jezerski

17 February 2022 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
BCBrooke Chapman
Brooke Chapman
SGSu Kah Goh
Su Kah Goh
FPFrank Parker
Frank Parker
SRSarah Romero
Sarah Romero
MSMarie Sinclair
Marie Sinclair
ATAdam Testro
Adam Testro

12 February 2019 in Liver International
Verified
Journal Article
Closed access
PDF file
MSMarie Sinclair
Marie Sinclair
RHRudolf Hoermann
Rudolf Hoermann
APAdam Peterson
Adam Peterson
ATAdam Testro
Adam Testro
PAPeter W. Angus
Peter W. Angus
PGPaul J. Gow
Paul J. Gow

26 February 2024 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PHPenelope Hey
Penelope Hey
RHRudolf Hoermann
Rudolf Hoermann
MSMarie Sinclair
Marie Sinclair
BCBrooke Chapman
Brooke Chapman
ATAdam Testro
Adam Testro
PGPaul Gow
Paul Gow
Summary: Background: Sarcopenia is associated with adverse outcomes in cirrhosis. Branched‐chain amino acids (BCAA) target several pathways that lead to muscle loss in this population.Aims: We aimed to evaluate the impact of BCAA supplementation on sarcopenia measures in patients with cirrhosis.Methods: We conducted a 12‐month double‐blinded, randomised, controlled trial of BCAA supplementation (30 g daily) compared to an equicaloric, equi‐nitrogenous whey protein in volunteers with cirrhosis and reduced muscle strength. The primary endpoint was an increase in grip strength and upper limb lean mass measured on DEXA. Mean‐adjusted differences (MAD, 95% CI) between groups at 6 and 12 months are reported as treatment effect using a linear mixed model for repeated measures.Results: A total of 150 volunteers entered the trial (74 BCAA, 76 control), with a median age of 58 years [IQR 48; 63] and MELD of 14 [12; 17]. At 12 months, 57% in the BCAA arm and 61% in the control arm met the primary endpoint (p = 0.80). No significant between‐group difference was found in grip strength (MAD ‐0.15 kg [−0.37; 0.06], p = 0.29) or upper limb lean mass (1.7 kg [−0.2; 3.6], p = 0.22) at 12 months. No significant differences in other body composition parameters, physical performance, frailty, rates of hospitalisation or mortality were found between the BCAA and the control group. Fatigue improved across the entire cohort, without significant between‐group differences. 15% of volunteers reported side effects, with distaste higher in the BCAA arm (p = 0.045).Conclusion: BCAA supplementation did not improve measures of muscle strength, mass or performance or physical frailty compared to a whey protein supplement in a randomised controlled setting. ACTRN12618000802202.

1 August 2019 in JHEP Reports
Verified
Journal Article
Open access
BCBrooke Chapman
Brooke Chapman
PGPaul Gow
Paul Gow
MSMarie Sinclair
Marie Sinclair
THTimothy Hanrahan
Timothy Hanrahan
PAPeter Angus
Peter Angus
ATAdam Testro
Adam Testro
Portal hypertension contributes to the pathogenesis of malnutrition and sarcopenia in cirrhosis via multiple mechanisms. Terlipressin is a vasopressin analogue that we administer via continuous outpatient infusion, as a bridge to transplantation in patients with hepatorenal syndrome or refractory ascites. We describe, for the first time, the impact of outpatient terlipressin on nutritional and muscle parameters. Nutrition (subjective global assessment), handgrip strength, dietary intake (energy, protein), frequency of paracentesis and severity of liver disease (model for end-stage liver disease score) were prospectively recorded at terlipressin commencement and follow-up (transplantation, cessation or census date). Nineteen patients were included (89% male, median age 59.6 years, median model for end-stage liver disease score 24), of whom 12 had hepatorenal syndrome and 7 had refractory ascites. All patients were malnourished at baseline, 63% (n = 12) had sarcopenic-range grip strength, and mean paracentesis frequency was 2.86 ± 1.62/month. Median duration of terlipressin was 51 days (interquartile range 29-222). Fourteen patients (74%) were transplanted, 2 delisted (10%) and 3 (16%) continued terlipressin. Energy and protein intake improved significantly following terlipressin, from 17.94 ± 5.43 kcal/kg to 27.70 ± 7.48 kcal/kg, and 0.74 ± 0.28 g/kg to 1.16 ± 0.31 g/kg, respectively (both p < 0.001). Handgrip strength increased from 25.36 ± 8.13 kg to 28.49 ± 7.63 kg (p = 0.001). Linear regression analysis demonstrated hand grip strength increased 0.075% for every 1-day of terlipressin (p = 0.005). The frequency of large-volume paracentesis reduced by 46%, to 1.57 ± 1.51/month (p = 0.001). Continuous terlipressin infusion reduces the complications of portal hypertension and is associated with an improvement in nutritional and muscle parameters in patients on the liver transplant waiting list, in whom such characteristics usually demonstrate progressive decline. This validates both the aetiological role of portal hypertension in malnutrition and represents a promising new anabolic therapy. Malnutrition and poor muscle strength are common in liver disease and often get worse while patients await liver transplant. Terlipressin is a medication used to treat portal hypertension in patients with hepatorenal syndrome. It is usually given for a few days or weeks in patients confined to hospital. Our centre provides outpatient terlipressin for weeks to months as a bridge to liver transplant. In patients treated with terlipressin at our hospital, we observed a substantial increase in their dietary intake and muscle strength, which may improve their quality of life and outcomes after liver transplant.